First-in-human phase i dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors

Geoffrey I. Shapiro, Eunice Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John Lyons, Daruka Mahadevan

Research output: Contribution to journalArticlepeer-review

73 Scopus citations

Fingerprint

Dive into the research topics of 'First-in-human phase i dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science